Optimising Patient Outcomes Throughout the Rheumatoid Arthritis Patient Journey: The Exception, the Standard, and the Rule - European Medical Journal
×

Browse

Optimising Patient Outcomes Throughout the Rheumatoid Arthritis Patient Journey: The Exception, the Standard, and the Rule

| Download as | PDF
Chairpeople:
Peter Taylor1
Speakers:
Ronald van Vollenhoven,2 Peter Taylor,1 Daniel Aletaha3
Disclosure:

Prof Taylor has received consulting fees, research or institutional support, and educational grants from AbbVie, Baxalta, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Epirus, Galapagos, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB. Prof van Vollenhoven has received consulting fees, research or institutional support, and educational grants from AbbVie, Amgen, Biotest, Bristol-Meyers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex. Prof Aletaha has received consulting fees, research or institutional support and educational grants from AbbVie, Bristol-Meyers Squibb, Eli Lilly, Grünenthal, Janssen, Merck, Pfizer, Sanofi/ Regeneron, and UCB.

Acknowledgements:

Writing assistance was provided by Melanie Sweetlove of ApotheCom.

Support:

The symposium and this article were sponsored and reviewed by UCB Pharma. The views and opinions expressed are those of the authors and not necessarily of UCB Pharma.

Citation
EMJ Rheumatol. ;3[1]:36-47.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Prof Peter Taylor opened the symposium focussed on optimisation of treatment for rheumatoid arthritis (RA) at each stage of the patient’s journey. Prof Ronald van Vollenhoven reviewed the evidence for first- line biologics in the ‘exceptional patient’ and explored which patients may be suitable for such treatments. Prof Taylor then expanded on how use of such treatments could be optimised and when to introduce biologic therapy for the so-called ‘standard’ patient. Finally, Prof Daniel Aletaha discussed treatment options and targets for patients who have failed on a biologic as ‘the rule’ in the treatment of RA.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the PDF above.